Abstract
Introduction

Alzheimer's disease (AD) is a neurological disorder characterized by profound memory loss and progressive dementia. The pathological and histological hallmarks of AD include amyloid plaques, neurofibrillary tangles and amyloidal angiopathy, accompanied by diffuse loss of neurons and synapses
. Environmental and genetic factors interact in the development of disease. Type 2 diabetes mellitus (DM) appears to be a significant risk factor for vascular dementia and AD in several epidemiological studies [2, 3] . Recent longitudinal studies have shown that AD and disorder of glucose metabolism are related [4, 5] . One explanation could be that vascular complications of diabetes result in neurodegenerative disease [6] . On the other hand, in addition to its peripheral metabolic effects, insulin also appears have important outcome on brain functions. A recent commentary offers two models of the link between Type 2 DM and AD: (1) 'central insulin resistance ' and (2) inflammation. Both mechanisms influence insulin sensitivity in the brain, finally leading to ␤-amiloid accumulation and, consequently, to AD [7] . Complex molecular mechanisms, referring to insulin and/or insulin-like growth factor-1 (IGF-1) signalling could link DM and AD [8] . In fact, there is evidence that altered insulin and/or IGF-1 signalling to brain cells is probably responsible of amyloid accumulation in AD [9] and several independent effects of insulin on brain functions and cognitive performance have been described [10] . Insulin resistance with associated hyperinsulinemia are the mechanisms suggested to explain the increased AD risk in diabetes [11] . Subsequent investigations demonstrated reduced blood glucose levels and increased insulin levels in patients with late onset AD compared to aged controls or patients with vascular dementia. Although the authors concluded that these findings did not support an association between diabetes and AD [12] , the same data were reinterpreted as an increased prevalence of insulin resistance in AD. The latter conclusion contradicts the finding that glucose administration could both increase plasma insulin levels and improve cognition in AD. Working under the assumption that increased insulin rather than glucose was responsible for the improvement in memory, further studies were used to demonstrate that the administration of insulin significantly improved memory performance in AD [8, 13] . [14] . In contrast, increases in plasma glucose that were not accompanied by increases in insulin levels did not influence cognitive performances [15] . The Rotterdam Study was one of the first epidemiology surveys to provide convincing evidence on a relationship between DM and dementia based on a significantly higher prevalence of dementia in patients with insulin-dependent (Type 1) DM compared to non-diabetic aged controls [3] . In addition, the possible association between DM-insulin resistance and degree of hippocampal and amygdala atrophy was investigated in vivo by magnetic resonance imaging [16] . The study showed that: (1) [18] . In this review, we will summarize current evidence supporting the association between insulin action, insulin receptors, IGF-1 and AD, and we will describe the underlying mechanisms. [19] . Although accumulated evidence indicate that insulin is derived from peripheral insulin and transferred by a transporter regulated way through the blood-brain barrier (BBB) [20, 21] [25, 26] . In the adult mammalian brain, two types of IR were found: a peripheral type and a neuron-specific type [27] [15] . The peripheral utilization of insulin reduces insulin transport into the brain, ultimately producing brain insulin deficiency [49] , and abrogating the beneficial influences of insulin on the brain functions [15] . Different [32, 40, 50] . Recent studies linked diabetes with AD [8, 9, 18] [17] . The revelation of a downregulation of brain insulin signalling in obesity and diabetes leads to the proposal brain insulin resistance [57] . The down-regulation of neural insulin action results associated to change of hippocampal electrical activity [58] and to modulation of GABA [59] , AMPA receptors [60] and N-L calcium channels [61] . [71] . Both in AD and in normal aging process mtDNA sustains high levels of oxidative damage [72] (Fig. 1) . In fact, it was observed the accumulation of A␤ within structural damaged mitochondria isolated from the brains of AD patients [72, 73] and transgenic brains [74] , which impair critical mitochondrial enzymes. Dysfunctional mitochondria release oxidizing free radicals, with peroxidation of membrane lipids and output of toxic aldehydes that cause considerable oxidative stress in AD and in normal aging brains [75] . Other essential proteins resulted oxidized, yielding carbonyl and nitrated derivatives, in neuronal cytoplasm in cerebral regions of neurodegeneration, in human brain affected by AD [76] . Subsequently, increased membrane permeability to calcium, and impaired glucose transport aggravate the energy imbalance [77] . Experimental model show that markers of oxidative damage precede pathological changes [78] . Destruction of mitochondria by the oxidation of a dynamic-like transporter protein may cause synapse loss in AD [79] . The 'receptor for advanced glycation end products' (RAGE) mediates A␤'s pro-oxidant effects on neural, microglial and cerebrovascular cells [80] . The RAGE receptor is a multi-ligand receptor, and one of its ligands is A␤ [80] . RAGE regulates several intracellular pathways [81] , such stimulates expression of b-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) [82] , an enzyme that is necessary for A␤ production. Moreover, RAGE seems to negatively affect the long-term potentiation (LTP) synaptic process of learning and memory [83] . Moreover, RAGE can induce its own expression through activation of the transcription factor NF-B [81] . RAGE also exists in a soluble form, structured by alternative splicing [84] or proteolytic cleavage by the metalloprotease 10 (ADAM 10) [85] . Soluble [86] . Indeed, studies have shown that sRAGE can inhibit the accumulation and aggregation of A␤ in mice brains [87] . In addition, it has been shown that sRAGE is present at lower levels in the blood and brain of AD patients [88] . Abnormal expression of RAGE forms in AD brain suggests that it is relevant to the pathogenesis of neuronal dysfunction and death.
Hyperinsulinemic euglycaemic clamp studies in humans showed improvement of attention in AD patients and neuroelectric changes in evoked potential induced by insulin
Insulin, IGF-1 in the brain
RAGE (sRAGE) contains the ligand-binding site, but does not have the signalling properties of full-length RAGE (flRAGE). Soluble RAGE should also have an increased propensity to scavenge A␤, thus increased protective properties. Nevertheless it was observed that flRAGE is engaged in positive feedback mechanisms, enhancing its own production, and limiting sRAGE proposed protective actions. This notion is supported by the finding that flRAGE expression is increased in AD brains
The insulin and IGF-1R system and phosphorylation
Neurofibrillary tangles are intracellular polymers of proteins, observed in cytoplasm of neurons [89] [90] . Studies in humans [91] and in mice [92] [93] . This implies a protective role of PP2A in neurodegeneration, which is consistent with the finding that PP2A activity is reduced in AD brains [94] . In vitro experiments demonstrated that phosphorylation is normally regulated by insulin and IGF-1 [95] . The [90] (Fig. 1) [102, 106] . [113, 114] , however this finding has not been universally replicated [115] . Increasing ␣-secretase activity, as mentioned above, increases the production of APPs␣, and has been reported to be neuroprotective and growth promoting [116] [127] . Although monomeric A␤ is not neurotoxic, the A␤ oligomers exhibits a marked toxicity [128] . The physiological role of ␤ peptides is still in part unclear, but it is involved in neuronal activation and connection mechanisms [129] . Neuronal activation rapidly increase A␤ secretion at the synapse, during the process of neurotransmitters release. Normal levels of A␤ at this site may modulate neuronal transmission and prevent hyperactivity [129] . It was assumed that imbalance between production, aggregation and clearance of peptides is considered initiating factor in AD [130] . The molecular mechanisms involved in the secretion, aggregation and toxicity of A␤ are still in part unknown [130] . For A␤ clearance several mechanisms have been described: (1) 
Although the mechanisms of increased GSK3␤ activation in AD can be readily explained on the basis of impaired insulin-IGF-1 signalling, the increased levels of ERK [107], AKT [108] and Cdk-5 [109] detected in AD brains cannot be attributed to these abnormalities. However, as noted earlier, GSK-3␤ can also be activated by oxidative stress. Review of the literature revealed that in addition to IGF-1 stimulation, ERK [110], AKT [111] and Cdk-5 [110] activities also can be increased in response to oxidative stress. Hyperinsulinemia, as well as complete lack of insulin, results in increased phosphorylation, leading to the hypothesis that hyperphosphorylation of follows an imbalance of insulin-regulated kinases and phosphatates [100].
Brain amyloid and insulin IGF-1 signalling
The amyloid plaques is formed by amyloid ␤ (A␤) peptides organized in fibrils intermixed with non-fibrillar forms of this peptide and are surrounded by dystrophic dendrites, axons, reactive astrocytes and activated microglia. A␤ consists of small hydrophobic peptides with N-and C-terminal heterogeneity, that is A␤1-40 and A␤1-42 which are proteolytically released from a large Type 1 integral membrane glycoprotein, the APP, via sequential cleavage by two aspartyl proteases, the ␤-and ␥-secretases [enzymatic complex, containing nicastrina, presenilina, preselin enhancer-2 (PEN-2), CD147] [112]. Initial ␤-secretase cleavage generates a soluble fragment from the NH2-terminus of APP, whereas the c-terminal fragment (␤-CTF) stays membrane bound. A␤40/42 activates Ca 2ϩ influx in neurons, hyperphosphorylation of protein (via activation of GSK3␤ and CDK5), leading to deposition of neurofibrillary tangles, impaired axonal transport and finally, to neuronal death (Fig. 2). Full-length APP can undergo alternative processing by ␣-secretase, generating a soluble APPs␣ ectodomain and a membrane-bound carboxy-terminal fragment, APP-CTF␣. Processing of APP by ␣-secretase is postulated to be protective in the context of AD, because the enzyme cleaves within the A␤-sequence, thereby preventing the production of A␤. Several studies have indicated that increased ␣-secretase-mediated processing of APP reduces the processing of APP by ␤-secretase and decrease A␤-production
enzymatic degradation by activated microglia or by insulin-degrading enzyme (IDE), neprilysin, endothelin-converting enzyme (ECE) and angiotensinconverting enzyme (ACE); (2) receptor-mediated transport across the BBB by binding to the low-density lipoprotein receptor-related protein (LRP), either directly or after binding to APO E and/or ␣2-macroglobulin (␣2M)
, to be delivered to peripheral sites of degradation, for example liver and kidney [50] . Concerning insulin resistance it has been shown that IDE expression is stimulated by the insulin resistance-IGF-1R cascade (Fig. 3) [131] . Furthermore, it has been suggested that increasing circulating IGF-1 levels lead to reduction of A␤ burden in aging rats [132] . It has been recently reported that membrane associated G protein-coupled receptor kinase-5 (GRK5) deficiency occurs during early AD [133] . In deficient GRK5 mice (tg2576-APPsw), A␤ accumulation resulted significantly increased [133] . IGF-1 administration resulted in reduction of cerebral A␤ load in these mice, whereas A␤ was elevated in CSF suggesting an increased A␤ elimination across the BBB or the choroid plexus [134] . Furthermore, it has been shown that the blockade of the IGF-1R in the choroid plexus triggers ADlike pathology [134] . In contrast, Lanz et al. [135] [136] . However, induction of insulin resistance by high fat diet [137] or intake of sucrose-sweetened water [138] leads to an aggravation of amyloid pathology in mouse models of AD. Furthermore, peripheral injection of supra physiologically high insulin doses but not of physiological doses leads to transient cerebral phosphorylation [98] , leading to the proposal that there is a dose-dependent effect of insulin resistance-IGF-1R signalling in the pathogenesis of AD.
Insulin, inflammation and AD
Inflammation has been proposed as a key pathogenetic factor for AD [139] . Elevated concentrations of interleukin (IL)-6 E2 isoprostane have been observed in CSF of patients with AD [140] . [142] ; however, during chronic hyperinsulinemia, insulin may exacerbate inflammatory responses and increase markers of oxidative stress [143] . [7] . Insulin may also modulate levels of eicosanoids such as F2-isoprostane via regulation of prostaglandin production in adypocites [145] . For example, Fig. 4 (1 [153] , and in peripheral lymphocytes from older adults compared with younger adults [154] . Abnormal levels of soluble TNF-R1 and -R2 have been documented in adults with diabetes and impaired glucose tolerance [155] , which reportedly normalize after a 3-weeks low calorie diet [156] . In the periphery, insulin reduces hepatic production of APO E and regulates its uptake by low-density lipoprotein receptor-related protein [157] . Fishel et al. showed that insulin reduced plasma APO E levels, an effect that increased with age. In contrast, insulin increased CSF APO E concentrations for older patients [158] . 
Furthermore, in vitro and animal studies suggest that inflammation interacts with processing and deposit of A␤ [141]. In the periphery, insulin modulates many aspects of the inflammatory network. Low doses of insulin exert anti-inflammatory effects
